An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade

Shuguang Zuo,1,2 Min Wei,1 Tiancheng Xu,1 Lingkai Kong,1 Bohao He,1 Shiqun Wang,1 Shibing Wang,1 Junhua Wu,1 Jie Dong,1 Jiwu Wei1

ABSTRACT

Background In addition to directly lysing tumors, oncolytic viruses also induce antitumor immunity by recruiting and activating immune cells in the local tumor microenvironment. However, the activation of the immune cells induced by oncolytic viruses is always accompanied by high-level expression of immune checkpoints in these cells, which may reduce the efficacy of the oncolytic viruses. The aim of this study is to arm the oncolytic vaccinia virus (VV) with immune checkpoint blockade to enhance its antitumor efficacy.

Methods Through homologous recombination with the parental VV, an engineered W-scFv-TIGIT was produced, which encodes a single-chain variable fragment (scFv) targeting T-cell immunoglobulin and ITIM domain (TIGIT). The antitumor efficacy of the VV-scFv-TIGIT was explored in several subcutaneous and ascites tumor models. The antitumor efficacy of VV-scFv-TIGIT combined with programmed cell death 1 (PD-1) or lymphocyte-activation gene 3 (LAG-3) blockade was also investigated.

Results The W-scFv-TIGIT effectively replicated in tumor cells and lysed them, and prompted the infected tumor cells to secret the functional scFv-TIGIT. Compared with control VV, intratumoral injection of W-scFv-TIGIT in several mouse subcutaneous tumor models showed superior antitumor efficacy, accompanied by more T cell infiltration and a higher degree of CD8+ T cells activation. Intraperitoneal injection of W-scFv-TIGIT in a mouse model of malignant ascites also significantly improved T cell infiltration and CD8+ T cell activation, resulting in more than 90% of the tumor-bearing mice being cured. Furthermore, the antitumor immune response induced by VV-scFv-TIGIT was dependent on CD8+ T cells which mediated a long-term immunological memory and a systemic antitumor immunity against the same tumor. Finally, the additional combination of PD-1 or LAG-3 blockade further enhanced the antitumor efficacy of VV-scFv-TIGIT, increasing the complete response rate of tumor-bearing mice.

Conclusions Oncolytic virotherapy using engineered W-scFv-TIGIT was an effective strategy for cancer immunotherapy. Administration of W-scFv-TIGIT caused a profound reshaping of the suppressive tumor microenvironment from ‘cold’ to ‘hot’ status. VV-scFv-TIGIT also synergized with PD-1 or LAG-3 blockade to achieve a complete response to tumors with poor response to W or immune checkpoint blockade monotherapy.

BACKGROUND

Oncolytic viruses (OVs) are natural or genetically engineered viruses that can selectively replicate in tumor cells and kill them without the destruction of normal cells.1 Currently, herpes simplex virus (HSV), adenovirus (ADV), and vaccinia virus (VV or VACV) are the three most commonly engineered viruses used in preclinical studies or clinical trials for cancer treatment.2 As a vaccine used to eradicate smallpox, VV has become the most widely studied virus in the poxvirus family. Several inherent biological characteristics of VV enable it to show advantages as an OV. First, VV has a large genome (approximately 192 kbp), which allows it to accommodate the insertion of large foreign DNA fragments into the viral genome.3 Second, VV does not enter the nucleus but completes the entire cycle of replication in the cytoplasm, which provides a safety advantage for VV as an OV since the viral DNA has less probability to integrate into the host genome.4 Third, the worldwide smallpox vaccination has accumulated a lot of safety data for the clinical application of oncolytic VV.5 Finally, VV can recruit immune cells and stimulate the body to produce a systemic antitumor immune response, which is essential for removing distant and metastatic tumor cells.6 These characteristics make VV one of the most promising candidates for oncolytic virotherapy. Pexastimogene devacirepvec (Pexa-Vec, JX-594) is an engineered VV in which a gene encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) is inserted as an immune adjuvant.6
Pexa-Vec is currently being evaluated in phase III clinical trials in patients with advanced hepatocellular carcinoma. However, it is still uncertain whether immune activation caused by genetic modification will produce better therapeutic effects.

Although the initial studies mainly focused on how to improve the selectivity and toxicity of OVs to tumor cells, oncolytic virotherapy is now regarded as an immunotherapy method for cancer due to its ability to increase tumor-specific effector and memory T cells.7 8 These activated T cells can strengthen the oncolysis of the virus at the site of virus injection, and they can migrate to a certain distance to kill the metastasized tumor cells, thereby producing an abscopal effect.9 Since the Food and Drug Administration (FDA)-approved talimogene laherparepvec (TVEC, a GM-CSF-modified HSV-1) for the treatment of metastatic melanoma in 2015,10 oncolytic virotherapy has received more attention in the field of cancer immunotherapy. However, the efficacy of OVs against solid tumors has not yet reached expectations, mainly due to the limitations of many factors such as physical barriers, tumor heterogeneity, and immunosuppressive tumor microenvironment (TME).11 There are multiple immunosuppressive pathways involved in the TME. Immune checkpoints (such as cytotoxic T-lymphotocyte antigen-4 (CTLA-4), programmed cell death 1 (PD-1), T-cell immunoglobulin and ITIM domain (TIGIT), T-cell immunoglobulin and mucin domain-3 (TIM-3), and lymphocyte-activation gene 3 (LAG-3)) are upregulated in tumor-infiltrating lymphocytes (TILs), which contribute to the formation of an immunosuppressive TME.12

The combination of OVs and immune checkpoint blockade (ICB) was explored to overcome the immunosuppressive TME.13 Recently, a phase Ib/II study demonstrated that the combined use of T-VEC and ipilimumab (Yervoy, a CTLA-4 blockade) appeared to be more effective than T-VEC or ipilimumab monotherapy.14 Another phase Ib clinical study showed that T-VEC synergized with pembrolizumab (Keytruda, the first FDA-approved PD-1 blockade) and improved the efficacy of pembrolizumab in the treatment of melanoma.15 In addition, OVs can be equipped with immune activators (such as cytokines,16 chemokines,18 costimulatory molecules,11 and immune checkpoint antibodies19–24) through genetic modification to further enhance the recruitment of T cells in the TME and reshape the immunosuppressive TME.25

Beyond CTLA-4 and PD-1, TIGIT is one of the most concerned immune checkpoints as the target of cancer immunotherapy.26 TIGIT belongs to an emerging member of the immunoglobulin superfamily, which also includes poliovirus receptor (PVR)-related immunoglobulin domain-containing (PVRIG, CD112R), T cell-activated increased late expression protein (Tactile, CD96), and DNAX accessory molecule-1 (DNAM-1, CD226).27 TIGIT, PVRIG, and Tactile are co-inhibitory receptors whereas DNAM-1 is a co-stimulatory receptor. These receptors mainly interact with the nectin and nectin-like (necl) family ligands (including PVR (also known as Necl-5, CD155) and PVR-related 1–4 (PVRL1–4, Nectin-1–4, CD111-114)) to form a complex regulatory network to control the activation of natural killer (NK) cells and T cells.28 TIGIT is weakly expressed on naïve T cells but frequently overexpressed on activated NK, CD8+ T cells, and regulatory T cells (Tregs).29 Furthermore, TIGIT is co-expressed with other co-inhibitory receptors (such as PD-1, CTLA-4, TIM-3, and LAG-3) on TILs, which is related to the exhaustion of activated CD8+ T cells.30 For these reasons, TIGIT has been considered a lucrative cancer immunotherapy candidate and several TIGIT monoclonal antibodies have been developed both in preclinical studies and clinical trials, particularly in combination with PD-1 or the other ICBs.31 32 Recently, studies have shown that TIGIT blockade significantly improved the antitumor efficacy of an oncolytic HSV-1 encoding a single-chain variable fragment (scFv) against PD-1.33 However, there are no reports on the use of scFv against TIGIT to arm the OV.

In the present study, we generated an engineered oncolytic VV, VV-scFv-TIGIT, which encoded a TIGIT scFv, and systematically investigated its antitumor efficacy in several mouse subcutaneous-tumor models and an ascites tumor model. We also investigated the efficacy of the combined application of the VV-scFv-TIGIT with PD-1 or LAG-3 blockade on colon tumor models.

**MATERIALS AND METHODS**

**Cell lines**

H22 cells were obtained from the China Center for Type Culture Collection (ID: 3111OC001CC0000309, Wuhan, China). HEK293 (Cat# CRL-1573), Hela-S3 (Cat# CCL-2.2), 4T1 (Cat# CRL-2539), B16/F10 (Cat# CRL-6475), and CT26 (Cat# CRL-6238) cell lines were purchased from the American Type Culture Collection (ATCC; Manassas, USA). MC38 cells (RRID: CVCL_B288) were obtained from the National Cancer Institute (USA). HEK293, Hela-S3, 4T1, MC38, CT26, and B16/F10 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Cat# 11965092, Gibco-Thermo Fisher Scientific, USA) supplemented with 10% fetal bovine serum (FBS; Cat#1600044, Gibco). H22 cells were maintained in Roswell Park Memorial Institute 1640 medium (Cat# 11875093, Gibco) supplemented with 10% FBS. Under suspension conditions, Hela-S3 cells were maintained in a spinner flask (Jetbiofil, Guangzhou, China). All cells were cultured in an incubator at 37°C and 5% CO₂ atmosphere.

**Construction of recombinant oncolytic VV**

The sequences of the variable domain of the heavy chain (VH) and the variable domain of the light chain (VL) are based on the hamster antimouse TIGIT monoclonal antibody (Clone 10a7) in the patent US20090258013A1. The gene fragment encoding scFv against TIGIT (scFv-TIGIT)
consisted of a human interleukin-2 (IL-2) signal peptide, an HA-tag, a VH, a (GGGGS)\(^3\) linker, and a VL. This gene fragment was synthesized by GenScript (Nanjing, China) and subcloned into a shuttle plasmid pHV-Control (online supplemental figure S1A) to construct the recombinant plasmid pVV-scFv-TIGIT (online supplemental figure S1B). In this plasmid, the expression of the scFv-TIGIT is driven by a synthesized early/later promoter (pSE/L), while the expression of the enhanced green fluorescent protein (EGFP; reporter gene) and the guanine-hypoxanthine phosphoribosyl transferase (GPT; screening gene) is driven by a p7.5K early/later promoter of VV.

To generate VV-scFv-TIGIT, the shuttle plasmid pVV-scFv-TIGIT was used for homologous recombination with a western reserve strain of VV (WRVV; Cat# VR-1354; ATCC). Briefly, HEK293 cells were infected with the WRVV at a multiplicity of infection (MOI) of 1 for 2 hours and then transfected with the pVV-scFv-TIGIT using the jetPRIME transfection reagent (Cat# 114–15, Polypuls; transfection; Illkirch, France). Forty-eight hours after the transfection, the formed EGFP-positive plaques were picked and seeded in plates with Hela-S3 cells. The conditional DMEM medium containing 250µg/mL xanthine (Cat# A601197, Sangon Biotech, Shanghai, China), 25µg/mL mycophenolic acid (Cat# A600640, Sangon), and 15µg/mL hypoxanthine (Cat# A500336, Sangon) was used to inhibit the growth of WRVV. After several cycles of picking and seeding, both PCR and DNA sequencing were used to confirm that the recombinant virus was no longer adulterated with WRVV. Then the purified virus was gradually expanded by Hela-S3 cells in 6-well plates, cell culture dishes, and cell culture spinner flasks. Similarly, pHV-Control was used for homologous recombination with WRVV to generate a control VV, namely VV-Control. The virus titer was determined by a TCID50 method. The calculation formula is as follows: virus titer\(=0.7\times10^{10}\times10^{\frac{S}{0.65}}\), where S is log10 (dilution), D is the sum of the positive ratios of EGFP in each dilution.

Western blot analysis

Tumor cells were seeded in 6-well plates at a density of \(5\times10^5\) cells per well and infected with VV-scFv-TIGIT or VV-Control at MOI of 1. After a 48-hour incubation, the cell culture supernatants were collected, and 10µL of the supernatants was taken out and mixed with a 2x loading buffer (Cat# P0015, Beyotime, Shanghai, China) in equal proportions. The protein samples were heated at 100°C for 5 min and then loaded on a sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel for electrophoresis. After the electrophoresis, the protein on the PAGE gel was transferred to a polyvinylidene fluoride (PVDF) membrane (Cat# K5MA6539B, Merck Millipore, Germany) using a semi-dry membrane transfer instrument. Then the PVDF membrane was incubated with a mouse anti-HA tag antibody (Clone 5E11D8, Cat# A01244, GenScript, Nanjing, China) at 4°C overnight, and then incubated with horseradish peroxidase (HRP)-labeled goat antimouse IgG (H+L) (Cat# A0216, Beyotime) at room temperature (RT) for 2 hours. After the incubation, an enhanced chemiluminescent kit (Cat# FD8000, FDbio, Hangzhou, China) was used to visualize the protein bands. A purified \~40kDa Multiple Tag fusion protein (Cat# M0101, GenScript, Nanjing, China) was served as a positive control for western blot analyses.

TIGIT binding and competition assay

For binding assay, 96-well plates were coated with recombinant mouse TIGIT protein (r-TIGIT; Cat# 50939-M38H, Sino Biological, Beijing, China) at a concentration of 10µg/mL. Then, supernatants containing scFv-TIGIT (prepared by infection of Hela-S3 cells with VV-scFv-TIGIT) were collected and added to the precoated wells and incubated at 4°C for 12 hours. After 3-time of wash, the mouse anti-HA tag antibody (0.1µg/mL) was added to each well and incubated at RT for 1 hour. Diluted (1: 2000) HRP-labeled secondary antibody (Cat# A0216, Beyotime) was added to each well after 3-time of wash and incubated at RT for 1 hour. After 3-time of wash, 100µL TMB substrate was added to each well and incubated at RT for 20 min. The optical density (OD) value was measured at 450nm using an absorbance microplate reader after 100µL of 2N sulfuric acid was added to stop the reaction.

For the competition assay, the coating procedure of the 96-well plate and the addition of the supernatants containing scFv-TIGIT were similar to the binding assay. After 3-time of wash, the cell culture supernatants containing Lucia-fused PVR (Lucia-PVR; prepared by transfection of HEK293 cells with a pVVF1α-Lucia-mPVR plasmid; online supplemental figure S1C) were added to the wells and incubated at 4°C for 12 hours. After 5-time of wash, 50µL of QUANTI-Luc substrate (Cat# rep-qlc1, InvivoGen, USA) was added to the wells, and the luciferase activity was immediately detected by the Glomax96 microplate luminescence detector.

Crystal violet staining

B16/F10, 4T1, MC38, and CT26 cells were seeded in 96-well plates at a density of \(5\times10^3\) cells per well, respectively, and cultured in an incubator at 37°C with 5% CO\(_2\) atmosphere. When the tumor cells reached 90% confluence, VVs were added to the wells at MOI of 0, 0.1, 1, 5, and 10. After a 72-hours incubation, the supernatants were removed and the 0.2% (w/v) crystal violet solution (Cat# C0121, Beyotime) was added to the wells for staining. After a 5 min incubation, the staining solution was removed from the wells and rinsed with dd H\(_2\)O 5 times. The image was acquired using a scanner. ImageJ software (V1.53) was used to calculate the area of living cells. The percentage was calculated using the area of each well relative to the area of the well with an MOI of 0 (no virus).
Briefly, tumor cells were seeded and infected as previously described and immediately infected with VVs at an MOI of 1. After culturing for 12, 24, 48, 72, and 96 hours, cell lysates were harvested and the virus titer was determined by a TCID50 method. The fold change was calculated relative to the virus titer at 12 hours.

**Animal experiments**

BALB/c mice and C57BL/6 mice were purchased from the Model Animal Research Center of Nanjing University (Nanjing, China). For the establishment of subcutaneous tumor models, the 4T1, MC38, CT26, or H22 tumor cells were implanted subcutaneously into the right flank of the mice. When the tumor reached approximately 50 or 100 mm³, the mice were randomly grouped and intratumorally treated with VVs or phosphate-buffered saline (PBS). Ascites cells were obtained by peritoneal paracentesis and flow cytometry was used to measure the proportion of tumor cells in the ascites.

For depletion of CD8⁺ T or NK cells, each mouse was injected intraperitoneally with 500 μg of anti-CD8α antibody (Clone YTS 169.4, Cat# BP0117, BioXCell, USA) or anti-NK1.1 antibody (Clone PK136, Cat# BP0036, BioXCell). Flow cytometry was used to check whether the in vivo depletion was successful.

For the combination therapy with VV-scFv-TIGIT and antimonue PD-1 antibody (αPD1, Clone RMP1-14, Cat# BE0146, BioXCell), subcutaneous MC38, and CT26 models were established as previously described. Each mouse was injected intraperitoneally with 200 μg of αPD1, which was initiated from the beginning of viral treatment and continued 6 or 7 times every 2 days. For the combination therapy with VV-scFv-TIGIT and antimouse LAG-3 antibody (αLAG-3, Clone C9B7W, Cat# BE0174, BioXCell), subcutaneous CT26 model was established as previously described. Each mouse was injected intraperitoneally with 200 μg of αLAG-3, which was initiated 2 days post the first viral injection and continued 3 times every 4 days.

**Extracellular and intracellular staining and flow cytometry**

The following antibodies were purchased from BioLegend (California, USA): phycoerythrin (PE) antimonue PD-L1 (Clone 10F.9G2, Cat# 124308), Allophycocyanin (APC) antimonue CD45 (Clone 30-F11, Cat# 103112), fluorescein-5-isothiocyanate (FITC) or PE antimonue CD3 (Clone 17A2, Cat# 100204; Cat# 100206), FITC or PE antimonue CD4 (Clone GK1.5, Cat# 100406; Cat# 100408), peridinin-chlorophyll-protein-cyanine5.5 (PerCP-Cy5.5) antimonue CD86 (Clone 53–6.7, Cat# 100754), PE antimonue CD49b (Clone HMz2, Cat# 103520), PE antimonue TIGIT (Clone 1G9, Cat# 142104), phycoerythrin (PE) antimouse LAG-3 (Clone 9A3, Cat# BE0174), PE antimouse PD-L1 (Clone 10F.9G2, Cat# 124308), Allophycocyanin (APC) antimonue CD45 (Clone 30-F11, Cat# 103112), fluorescein-5-isothiocyanate (FITC) or PE antimonue CD3 (Clone 17A2, Cat# 100204; Cat# 100206), FITC or PE antimonue CD4 (Clone GK1.5, Cat# 100406; Cat# 100408), peridinin-chlorophyll-protein-cyanine5.5 (PerCP-Cy5.5) antimonue CD86 (Clone 53–6.7, Cat# 100754), PE antimonue CD49b (Clone HMz2, Cat# 103520), PE antimonue TIGIT (Clone 1G9, Cat# 142104), phycoerythrin (PE) antimouse LAG-3 (Clone 9A3, Cat# BE0174), PE antimouse PD-L1 (Clone 10F.9G2, Cat# 124308), Allophycocyanin (APC) antimonue CD45 (Clone 30-F11, Cat# 103112), fluorescein-5-isothiocyanate (FITC) or PE antimonue CD3 (Clone 17A2, Cat# 100204; Cat# 100206), FITC or PE antimonue CD4 (Clone GK1.5, Cat# 100406; Cat# 100408), peridinin-chlorophyll-protein-cyanine5.5 (PerCP-Cy5.5) antimonue CD86 (Clone 53–6.7, Cat# 100754), PE antimonue CD49b (Clone HMz2, Cat# 103520), PE antimonue TIGIT (Clone 1G9, Cat# 142104), phycoerythrin (PE) antimouse LAG-3 (Clone 9A3, Cat# BE0174), PE antimouse PD-L1 (Clone 10F.9G2, Cat# 124308), Allophycocyanin (APC) antimonue CD45 (Clone 30-F11, Cat# 103112), fluorescein-5-isothiocyanate (FITC) or PE antimonue CD3 (Clone 17A2, Cat# 100204; Cat# 100206), FITC or PE antimonue CD4 (Clone GK1.5, Cat# 100406; Cat# 100408), peridinin-chlorophyll-protein-cyanine5.5 (PerCP-Cy5.5) antimonue CD86 (Clone 53–6.7, Cat# 100754), PE antimonue CD49b (Clone HMz2, Cat# 103520), PE antimonue TIGIT (Clone 1G9, Cat# 142104), phycoerythrin (PE) antimouse LAG-3 (Clone 9A3, Cat# BE0174), PE antimouse PD-L1 (Clone 10F.9G2, Cat# 124308), Allophycocyanin (APC) antimonue CD45 (Clone 30-F11, Cat# 103112), fluorescein-5-isothiocyanate (FITC) or PE antimonue CD3 (Clone 17A2, Cat# 100204; Cat# 100206), FITC or PE antimonue CD4 (Clone GK1.5, Cat# 100406; Cat# 100408), peridinin-chlorophyll-protein-cyanine5.5 (PerCP-Cy5.5) antimonue CD86 (Clone 53–6.7, Cat# 100754), PE antimonue CD49b (Clone HMz2, Cat# 103520), PE antimonue TIGIT (Clone 1G9, Cat# 142104),
directly adjusted to 2×10^6 cells/mL. For extracellular
2×10^7 cells/mL. For tumor cell lines, the adherent cells
mice. After cell counting, the cells were adjusted to
advance, and the suspension-
(4T1, MC38, CT26) were digested with 0.5% trypsin in
theses from the peritoneal cavity of the tumor-
Jetbiofil). Then, the cells were counted and adjusted to
syringe plungers on 70
splenocytes, the spleens were obtained from the sacri-
600
Ascites fluids were collected by paracentesis from the
Measurement of cytokines
using FlowJo software (TreeStar; OR, USA).
analyzed by flow cytometry. Data analysis was performed
added respectively and incubated for 30
science), and then the corresponding antibodies were
with 1×permeabilization buffer (Cat# 00-
For intracellular staining, the fixed cells were ruptured
using a FACS Calibur cytometer (BD; California, USA).
Servicebio, Wuhan, China) solution and directly analyzed
with 4% (w/v) paraformaldehyde (PFA, Cat# G1101,
for 15
incubated with the fluorescent monoclonal antibodies
staining, the preprepared single-
was purchased from eBioscience-
zyme B (Clone QA18A28, Cat# 396406), FITC antitumor
CD62L (Clone MEL-
CD22- (Cat# 506306), PE antihuman/mouse gran-
zenzyme B (Clone QA18A28, Cat# 396406), FITC antitumor
CD62L (Clone MEL-14, Cat# 104406), PE antitumor/
human CD44 (Clone IM7, Cat# 103024) and PE rat
IgG2b (x isotype control; Clone RTK4530, Cat# 400607).
FITC antitumor NK1.1 (Clone PK136, Cat# 11-3911-82)
which was purchased from eBioscience-Thermo Fisher Scien-
tific (USA).
For the preparation of single-cell suspensions of tumor
tissues, mice were anesthetized and sacrificed, and the
tumor tissues were harvested and placed in a serum-free
medium (Cat# H740KJ, Basalmedia) with 0.2% colla-
genase IV (Cat# C4-22-1G, Sigma-Aldrich, Germany).
Then, the tumor tissues were cut into 1–2 mm pieces,
digested for 2 hours, and passed through 70 µm nylon
filters (Cat# CSS013070, Jetbiofil, Guangzhou, China)
to obtain the single-cell suspensions. After that, the
collagenase was removed by centrifugation, and the
cell pellets were suspended in the serum-free medium
and adjusted to 2×10⁷ cells/mL. For the preparation of
splenocytes, the spleens were obtained from the sacri-
ficed mice and ground into single-cell suspensions using
syringe plungers on 70 µm nylon filters (Cat# CSS013070,
Jetbiofil). Then, the cells were counted and adjusted to
5×10⁶ cells/mL. Ascites cells were obtained by paracen-
tesis from the peritoneal cavity of the tumor-bearing
mice. After cell counting, the cells were adjusted to
2×10⁷ cells/mL. For tumor cell lines, the adherent cells
(4T1, MC38, CT26) were digested with 0.5% trypsin
in advance, and the suspension-cultured H22 cells were
directly adjusted to 2×10⁶ cells/mL. For extracellular
staining, the prepurified single-cell suspensions were
incubated with the fluorescent monoclonal antibodies
for 15 min at RT. After incubation, the cells were fixed
with 4% (w/v) paraformaldehyde (PFA, Cat# G1101,
Servicebio, Wuhan, China) solution and directly analyzed
using a FACs Calibur cytometer (BD; California, USA).
For intracellular staining, the fixed cells were ruptured
with 1×permeabilization buffer (Cat# 00-8333-56, eBio-
sience), and then the corresponding antibodies were
added respectively and incubated for 30 min in the dark.
After washing with PBS once, an appropriate amount
of PBS was added to resuspend the cells and immediately
analyzed by flow cytometry. Data analysis was performed
using FlowJo software (TreeStar; OR, USA).

Measurement of cytokines
Ascites fluids were collected by paracentesis from the
peritoneal cavity of the mice. Samples were centrifuged at
600g for 5 min at RT and the supernatants were collected.
ELISA MAX Standard Sets of IFN-γ (Cat# 430801,
Biologend), IL-2 (Cat# 431001), IL-6 (Cat# 431301),
and IL-10 (Cat# 431411) were used to determine the
concentration of the corresponding cytokines. The measurement method was based on the manufacturing
protocol.
For co-culture assay, C57BL/6 mice cured of H22 by
VV-scFv-TIGIT were re-inoculated with 2×10⁶ H22 cells
intraperitoneally. The re-inoculation was performed once
a month and a total of two inoculations. Seven days after
the second intraperitoneal inoculation of H22 cells, the
mice were sacrificed after anesthesia to obtain spleens
and prepare splenocytes. The cultured H22 cells were
seeded into a 6-well plate at the density of 3×10⁵ cells
per well, and then 3×10⁶ splenocytes were added to make the
ratio of splenocytes to tumor cells 10:1. The cells were
harvested after 72 hours of co-culture. The preparation of
the supernatants and the measurement of cytokines were
performed as previously described.

Immunohistochemistry
The resected tumor tissues were fixed in 4% PFA (Cat# G1101, Servicebio) and embedded in paraffin blocks.
Sections were cut at a thickness of 5 µm from the paraffin-
embedded blocks, deparaffinized by immersion in xylene
(10 min, ×2), and rehydrated in graded ethanol (100%
for 3 min, ×2; 95% for 3 min; 70% for 3 min; 50% for
3 min) and incubated with 3% (w/v) hydrogen peroxide
to block endogenous peroxidase activity. After that, the
sections were incubated with a rabbit antitumor CD8α
antibody (1:200 dilution; Cat# ab217344, Abcam, USA)
and an HRP goat antirabbit IgG secondary antibody
(1:200 dilution; Cat# G1213, Servicebio). Finally, the
sections were stained with 3′,5-diaminobenzidine (Cat# G1212-2, Servicebio) and counterstained with 37% (w/v)
hematoxylin (Cat# G1004, Servicebio).

Statistical analyses
All Statistical analyses were performed using Prism 8.2.1
(GraphPad Software, California, USA). The statistical
differences among the groups were analyzed by analysis
of variance. The Kaplan-Meier method was used to draw
the survival curve, and the Log-Rank test was used to
calculate the statistical significance among the groups.
In all statistical analyses, p<0.05 was considered statistically
significant.

RESULTS
Generation and characterization of recombinant oncolytic VVs
Through homologous recombination, we generated a
recombinant oncolytic VV, VV-scFv-TIGIT, with a gene
fragment of scFv against TIGIT in the backbone of a
thymidine kinase (TK; J2R)-destroyed WR-VV (figure 1A).
We also generated a control VV, VV-control, with no scFv
insertion in the TK area. The VV-scFv-TIGIT virus exhib-
ted green fluorescent plaques in Hela-S3 cells, allowing
it to be easily picked and purified as a monoclonal virus
(figure 1B). The scFv-TIGIT was efficiently secreted
from VV-scFv-TIGIT-infected Hela-S3 cells as detected
by western blot assay (figure 1C). Similarly, four murine
Figure 1  Generation and characterization of VV-scFv-TIGIT. (A) A schematic diagram of homologous recombination. To generate VV-scFv-TIGIT, the shuttle plasmid pVV-scFv-TIGIT was used for homologous recombination with a western reserve (WR) strain of VV by using the left (L) and right (R) flanking sequences of thymidine kinase (TK), T2A, thoseasigna virus 2A. (B) The virus plaque formed in Hela-S3 cells infected with VV-scFv-TIGIT. (C) Western blot analysis of HA-tagged scFv-TIGIT in the supernatants of Hela-S3 cells, a Multiple Tag was used as the positive control. (D) Western blot analysis of scFv-TIGIT in four murine tumor cell lines. (E) ELISA was used to detect the binding of the secreted scFv-TIGIT to the recombinant TIGIT (r-TIGIT). (F) Luciferase-linked immunosorbent assay was used to test the blocking effect of scFv-TIGIT on the binding of PVR and r-TIGIT. (G, H) Crystal violet staining was used to detect the oncolytic ability of VVs against murine tumor cells. (I) TCID50 method was used to detect viral replication in murine tumor cells. p<0.0001. scFv, single-chain variable fragment; TIGIT, T-cell immunoglobulin and ITIM domain; VV, vaccinia virus.
tumor cells (4T1, MC38, CT26, and H22) infected with VV-scFv-TIGIT also efficiently secreted the scFv-TIGIT (figure 1D). ELISA and luciferase assay showed that the secreted scFv-TIGIT effectively bound to r-TIGIT (figure 1E), and effectively blocked the binding of PVR to r-TIGIT (figure 1F). A crystal violet staining assay showed that both VV-scFv-TIGIT and VV-Control showed dose (MOI)-dependent oncolytic activity against 4T1, MC38, CT26, and B16/F10 cells (figure 1G). Both crystal violet staining and MTT assay confirmed that there was no statistical difference in the oncolytic activity between VV-scFv-TIGIT and VV-Control (figure 1H; online supplemental figure S2A). Moreover, VV-scFv-TIGIT and VV-Control showed similar replication characteristics in murine tumor cell lines (figure 1I; online supplemental figure S2B). These data indicated that the replication and oncolytic ability of the recombinant VV was not affected by the scFv-TIGIT transgene.

**Antitumor activity of VVs on subcutaneous tumor models**

We evaluated the antitumor activity of the VVs in four subcutaneous tumor models (4T1, CT26, H22 (figure 2A), and MC38 (figure 2B)) in immunocompetent BALB/c (figure 2A) and C57BL/6 mice (figure 2B). Although the administration of VV-Control showed superior antitumor effects than PBS in the CT26 model in terms of inhibiting tumor growth and prolonging the survival of mice, it did not show any superior antitumor effects than PBS in the 4T1, H22, and MC38 models. In all four models, mice treated with VV-scFv-TIGIT had significantly lower tumor volume and prolonged survival compared with mice treated with VV-Control or PBS (figure 2A,B). Of note, nearly 20% of the CT26 tumor-bearing mice treated with VV-scFv-TIGIT achieved complete remission (CR), while none of the mice treated with VV-Control or PBS achieved CR (figure 2A; online supplemental figure S3). There was no significant difference in body weight among the three groups of mice (figure 2A,B). These data indicated that VV-scFv-TIGIT is superior to VV-Control in reducing tumor burden and prolonging the survival of tumor-bearing mice.

**Intratumoral injection of VVs induced infiltration of immune cells**

We evaluated the infiltration of immune cells after intratumoral injection of the VVs in the CT26 subcutaneous tumor model (figure 3A). Consistent with the previous results, administration of VV-scFv-TIGIT significantly delayed the tumor growth (p<0.05 vs VV-Control, p<0.01 vs PBS; figure 3B,C), but it did not affect the body weight of the mice (p>0.05; figure 3D). Flow cytometry analysis showed that intratumoral injection of VV-scFv-TIGIT significantly increased the infiltration of CD45+ lymphocytes, CD3+ T, CD4+ T, and CD8+ T cells compared with either VV-Control or PBS, but did not cause obvious changes in NK and NKT cells (figure 3E,F). Next, we evaluated the expression of four immune checkpoint (TIGIT, PD-1, TIM-3, and LAG-3) and one activation marker (CD107A) on T cells (figure 3G–I). Compared with PBS, injection of VV-Control only increased the composition of TIGIT+ cells in the CD8+ T cells, and increased the composition of TIGIT+ and LAG-3+ cells in the CD4+ T cells, whereas injection of VV-scFv-TIGIT significantly increased the composition of TIGIT+, PD-1+, TIM-3+, LAG-3+ and CD107A+ cells in the CD8+ T cells and increased the composition of TIGIT+ and LAG-3+ cells in the CD4+ T cells. In particular, the composition of LAG-3+ and CD107A+ cells in the CD8+ T cells were significantly different between the VVs-scFv-TIGIT and VV-Control injection groups (p<0.05; p<0.01). Moreover, VV-scFv-TIGIT significantly increased the proportion of CD8+ T cells in the splenocytes (p<0.05 vs PBS; figure 3J). Subsequently, we confirmed the infiltration of CD8+ T cells by immunohistochemistry. Consistent with the flow cytometry analysis, VV-scFv-TIGIT significantly increased the tumor infiltration of CD8+ T cells compared with either VV-Control or PBS (p<0.001; p<0.0001; online supplemental figure S4). As expected, comparable virus titers were observed in tumors of mice treated with VV-scFv-TIGIT or VV-Control, whereas no virus was detected in the tumor tissues of PBS-treated mice and in the sera of the three groups of mice (figure 3K). Altogether, these results indicated that the VVs-scFv-TIGIT could reshape the TME by recruiting immune cells and activating the tumor-infiltrating CD8+ T cells.

**Enhanced antitumor immunity in the ascites tumor models**

We evaluated the ability of VV-scFv-TIGIT to recruit immune cells and its antitumor activity on an H22 ascites model in C57BL/6 mice (online supplemental figure S5A; figure 4A). Through dynamic observation, we found that tumor cells and lymphocytes were always maintained in a fixed ratio in the ascites of mice treated with PBS, showing a ‘cold’ TME lacking lymphocytes (approximately 1%). However, intra-peritoneal injection of VV-Control or VV-scFv-TIGIT gradually reduced the proportion of tumor cells, while gradually increased the proportion of CD45+ lymphocytes (online supplemental figure S5B,C), which made the TME become ‘hot’. Of note, the tumor cells in the ascites of VVs-scFv-TIGIT-treated mice almost disappeared (2.09%) 2 days post the third TV treatment, accompanied by a higher proportion (25.2%) of lymphocytes (online supplemental figure S5B,C). Two days post the second TV treatment, VVs-scFv-TIGIT-treated mice had a significantly lower proportion of tumor cells and a higher proportion of lymphocytes, NK, CD3+ T, CD4+ T, and CD8+ T cells in the ascites compared with PBS-treated or VV-Control-treated mice (figure 4B). Both VVs-scFv-TIGIT and VV-Control significantly increased the composition of TIGIT+, PD-1+, TIM-3+, and LAG-3+ cells in the CD8+ T cell population compared with PBS. Of note, VVs-scFv-TIGIT was more potent in increasing the proportion of TIM-3+CD8+, and LAG-3+CD8+ T cells than VV-Control (figure 4C). Moreover, VVs-scFv-TIGIT was shown to activate CD8+ T cells more effectively than VV-Control, which is mainly reflected in the increased expression of CD107a on the cell surface, and the increased expression of intracellular IFN-γ, TNF-α, and granzyme B (figure 4D). Mice treated with VVs-scFv-TIGIT also showed a higher level of IFN-γ, IL-2, IL-6, and IL-10 in ascites than mice treated with VV-Control or PBS (figure 4E). Consistent with these results, >90% (15/16) of
Figure 2  Intratumoral injection of VV-scFv-TIGIT enhanced antitumor efficacy in subcutaneous (S.C.) tumor models. (A) The S.C. tumor models of 4T1, CT26, and H22 were established by inoculation of corresponding cells on the right flank of BALB/c mice. Seven days after tumor inoculation, mice were administered intratumorally (I.T.) with the indicated VV or PBS. (B) MC38 S.C. tumor model was similarly established on C57BL/6 mice and injected intratumorally with the indicated VV or PBS 5 days after the tumor inoculation. Tumor volume and body weight were measured every 2 days. Error bars represent SD. Once the tumor volume exceeded 2000 mm³, the mouse was considered dead. ns, no significant differences; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. PBS, phosphate-buffered saline; scFv, single-chain variable fragment; TIGIT, T-cell immunoglobulin and ITIM domain; VV, vaccinia virus.
Figure 3  Intratumoral injection of VV-scFv-TIGIT enhanced infiltration of immune cells in the CT26 tumor model. (A) Treatment scheme of CT26 subcutaneous (S.C.) tumor model. (B) Mean tumor volume of mice. (C) Individual tumor growth curve of mice. (D) Body weight of mice. (E) Representative diagram of flow cytometric analysis of immune cell infiltration in tumor tissues. (F) Flow cytometric analysis of the proportion of lymphocytes and their subpopulations in tumor tissues. (G) Flow cytometric analysis of the expression of immune checkpoints on CD8+ T cells. (H) Flow cytometric analysis of the expression of immune checkpoints on CD4+ T cells. (I) Flow cytometric analysis of the expression of CD107A on CD8+ T cells. (J) Flow cytometric analysis of the proportion of lymphocytes subsets in splenoocytes. (K) The virus titers in tumor tissues or sera of mice were quantified by the TCID50 method. ns, no significant differences; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. PBS, phosphate-buffered saline; scFv, single-chain variable fragment; TIGIT, T-cell immunoglobulin and ITIM domain; VV, vaccinia virus.
Figure 4  Intraperitoneal injection of VV-scFv-TIGIT enhanced antitumor efficacy in ascites tumor models. (A) Treatment scheme of H22 ascites model. (B) Flow cytometric analysis of the proportion of tumor cells, lymphocytes, and their subpopulations in tumor tissues. (C) Flow cytometric analysis of the expression of immune checkpoint molecules on the surface of CD8+ T cells. (D) Surface and intracellular staining of CD8+ T cells for T cell activation markers and analysis by flow cytometry. (E) The levels of cytokines in the ascites were detected by ELISA. (F) Kaplan-Meier survival curves of tumor-bearing mice. ns, no significant differences; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. PBS, phosphate-buffered saline; scFv, single-chain variable fragment; TIGIT, T-cell immunoglobulin and ITIM domain; VV, vaccinia virus.
mice treated with VV-scFv-TIGIT achieved CR of ascites, while only 25% (4/16) of mice treated with VV-Control achieved CR (figure 4F).

We further evaluated the antitumor activity of VV-scFv-TIGIT on another H22 ascites model in BALB/c mice (online supplemental figure S6A). Consistent with previous results, intraperitoneal injection of VV-scFv-TIGIT significantly increased the proportion of lymphocytes (p<0.05 vs VV-Control; p<0.001 vs PBS), CD4 + T cells (p<0.01 vs PBS), and CD8 + T cells (p<0.01 vs VV-Control; p<0.0001 vs PBS) in the ascites (online supplemental figure S6B,C). Nearly 40% (3/8) of the mice treated with VV-scFv-TIGIT achieved CR of ascites, while other mice showed continuous ascites progression and eventually died (online supplemental figure S6D). These data, together with the previous data, indicated that VV-scFv-TIGIT had superior antitumor efficacy and a stronger ability to recruit and activate CD8 + T cells in ascites models.

**CD8 + T cells mediated the antitumor immunity of VV-scFv-TIGIT**

To reveal the role of CD8 + T and NK cells in mediating the antitumor activity of VV-scFv-TIGIT, we depleted these two types of lymphocytes and analyzed whether their depletion would affect the antitumor efficacy of VV in the ascites model (figure 5A). As expected, the CD8 + T and NK cells in peripheral blood were completely depleted 1 day after the injection of the corresponding monoclonal antibody (figure 5B) and their depletion was maintained for 2 weeks (data not shown). Similarly, these cells in ascites were depleted when the ascites formed (3 days after the antibody injection) (figure 5C). Consistent with previous results, treatment of mice with VV-scFv-TIGIT significantly decreased the proportion of tumor cells and increased the proportion of lymphocytes, NK, NKt, CD3 + T, CD4 + T, and CD8 + T cells in the ascites (figure 5D,E). In contrast, the depletion of CD8 + T cells reversed all these increases, making these cells in VV-scFv-TIGIT-treated mice reach the same or lower levels as those in PBS-treated mice (figure 5E). Although the depletion of NK cells also significantly decreased the NKt, CD3 + , CD4 + , and CD8 + T cells, these cells still showed a higher trend in VV-scFv-TIGIT-treated mice than in PBS-treated mice (figure 5E). Moreover, IFN-γ, IL-2, IL-6, and IL-10 were significantly reduced in response to the depletion of CD8 + T cells (figure 5F). Consistent with these results, the depletion of CD8 + T cells completely abrogated the antitumor efficacy of VV-scFv-TIGIT, while the depletion of NK cells had no obvious impact (figure 5G). Moreover, all these cured mice did not develop ascites after continuous observation for 180 days (figure 5G). These results indicated that CD8 + T cell is a major immune cell type that mediated the antitumor immunity of VV-scFv-TIGIT.

**Treatment of mice with VV-scFv-TIGIT established long-term tumor-specific immunological memory and systemic antitumor immunity**

To examine the tumor-specific immunological memory, 10 of 15 mice previously cured of H22 by VV-scFv-TIGIT were twice intraperitoneally and once subcutaneously rechallenged with the same tumor cells, and once subcutaneously challenged with MC38 cells (figure 6A). All age-matched treatment-naïve mice developed cancerous ascites and eventually died after being challenged by H22 cells in the peritoneum, while all the previously cured mice did not develop ascites after either the first or the second H22 rechallenge (figure 6B). Similarly, no subcutaneous tumors were formed in these previously cured mice after a subcutaneous rechallenge of H22 cells. However, all these cured mice did not reject MC38 cells and developed subcutaneous tumors (figure 6C). Consistent with these results, the proportion of naïve (CD62L CD44 + ) CD8 + T cells in splenocytes of mice that had rejected H22 tumor rechallenge decreased (p<0.0001 vs treatment-naïve mice), while the total CD8 + T cells and their central memory (CD62L CD44 + ) and effector memory (CD62L CD44 + ) subsets increased (p<0.0001, p<0.001, p<0.001, respectively; figure 6D–E). Furthermore, co-culture of H22 cells with splenocytes from the H22 rechallenged mice significantly reduced the proportion of the tumor cells and increased the production of IFN-γ and IL-2 in the co-culture system (all p<0.05 vs treatment-naïve mice; figure 6F).

Next, to investigate whether intraperitoneal injection of VV-scFv-TIGIT could establish a systemic antitumor immunity against the subcutaneous tumor, we established a mouse dual tumor model by inoculation of the H22 cells intraperitoneally and subcutaneously (online supplemental figure S7A). To our surprise, all the ascites in mice that had been intraperitoneally injected with VV-scFv-TIGIT disappeared (online supplemental figure S7B). Meanwhile, the subcutaneous tumors in 9 of 11 mice also completely regressed (online supplemental figure S7C). In contrast, all of the PBS-treated mice died of ascites (online supplemental figure S7B,E), and none of these mice showed regression of subcutaneous tumors (online supplemental figure S7D,E). Moreover, no virus was detected in the subcutaneous tumors of the mice treated with an intraperitoneal injection of VV-scFv-TIGIT (online supplemental figure S7F). These data indicated that the treatment of tumor-bearing mice with VV-scFv-TIGIT established long-term tumor-specific immunological memory and systemic antitumor immunity.

**Combination therapy with αPD-1 or αLAG-3 improved antitumor efficacy of VV-scFv-TIGIT in colon cancer models**

First, we analyzed the correlation between the expression of TIGIT and the other two immune checkpoints (PD-1 and LAG-3) based on the expression profile data of The Cancer Genome Atlas. As shown in online supplemental figure S8A,B, the expression of TIGIT was positively correlated with the expression of PD-1 or LAG-3 in pan-cancers (33 types) and some of them, including but not limited to breast cancer, liver hepatocellular carcinoma, and colorectal carcinoma. Next, by treating tumor cells with VV-control or VV-scFv-TIGIT, we also investigated whether the infection of these two VVs affected
**Figure 5**  CD8+ T cells mediated the antitumor immunity of VV-scFv-TIGIT. (A) Treatment scheme of H22 ascites model. (B, C) The depletion of CD8+ T cells and NK cells in the blood (B) or ascites (C) of mice was analyzed by flow cytometry. (D) Representative diagram of flow cytometric analysis of tumor cells and lymphocytes in the ascites. (E) Flow cytometric analysis of the proportion of tumor cells, lymphocytes, and their subpopulations in the ascites. (F) The levels of cytokines in the ascites were detected by ELISA. (G) Kaplan-Meier survival curves of tumor-bearing mice. ns, no significant differences; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. PBS, phosphate-buffered saline; scFv, single-chain variable fragment; TIGIT, T-cell immunoglobulin and ITIM domain; VV, vaccinia virus.
the expression of PD-L1 on 4T1, CT26, MC38, and H22 cells (online supplemental figure S9). After 48 hours of treatment, the two viruses showed similar infection efficiency in the four tumor cell lines, in which >70% of 4T1 cells were infected by the VVs and expressed EGFP, while 50%–60% of CT26 or MC38 cells were infected, and only 20% of H22 were infected. In response to VV infection, the expression of PD-L1 on the surface of the four tumor cell lines was upregulated and showed a similar degree of upregulation between the two viruses.

To explore whether the combined application of αPD-1 could enhance the antitumor efficacy of VV-scFv-TIGIT, we used an intratumoral injection of VV-scFv-TIGIT and intraperitoneal injection of αPD-1 to treat the MC38 subcutaneous tumor model (online supplemental figure S10A). As shown in online supplemental figure S10B, monotherapy with VV-scFv-TIGIT or αPD-1 significantly inhibited tumor growth (p<0.01 and p<0.01 vs PBS). At the same time, there was no significant difference in the tumor volume of mice between the two monotherapies (p>0.05). However, combined therapy with VV-scFv-TIGIT and αPD-1 further reduced the tumor volume of mice (p<0.05 vs VV-scFv-TIGIT; p<0.01 vs αPD-1; p<0.001 vs PBS), in which one mouse achieved tumor CR (online supplemental figure S10C). Consistent with these results, monotherapy with VV-scFv-TIGIT or αPD-1 and

Figure 6  Treatment of mice with VV-scFv-TIGIT established long-term tumor-specific immunological memory. (A) Rechallenge scheme. (B) Kaplan-Meier survival curves of the treatment-naïve mice or the mice cured of H22 by VV-scFv-TIGIT. (C) Tumor volumes of previously cured mice rechallenged with H22 or MC38 cells subcutaneously. (D) Rechallenge scheme and representative diagram of flow cytometric analysis of memory T cells. (E) Flow cytometric analysis of the proportion of CD8+ T cells, naïve (CD62L+CD44−), effector memory (CD62L−CD44+) and central memory (CD62L+CD44+) CD8+ T cells. (F) Co-culture of H22 cells with splenocytes from the H22 rechallenged mice. The proportion of lymphocytes and tumor cells in the co-culture system was detected by flow cytometry. The levels of cytokines in the co-culture system were detected by ELISA. ns, no significant differences; *p<0.05; ***p<0.001; ****p<0.0001.

scFv, single-chain variable fragment; TIGIT, T-cell immunoglobulin and ITIM domain; VV, vaccinia virus.
the combination therapy with both of them significantly prolonged the survival time of mice (p<0.05, p<0.05, and p<0.01 vs PBS). However, there was no significant difference in survival among these three groups of mice (online supplemental figure S10D).

We also evaluated the antitumor activity of the combined application of VV-scFv-TIGIT and αPD-1 on the CT26 colon cancer model (figure 7A). Monotherapy with αPD-1 or VV-scFv-TIGIT and the combination of the two significantly inhibited tumor growth (p<0.05, p<0.05 or p<0.01 vs PBS). The combination therapy showed a trend of smaller tumor volume than mice treated with VV-scFv-TIGIT or αPD-1 alone (figure 7B). One-ninth of αPD-1-treated, two-ninths of VV-scFv-TIGIT-treated, and five-ninths of co-treated mice achieved tumor CR, and one-ninth of the co-treated mice achieved partial remission (PR), while none of the eight mice treated with PBS achieved CR or PR (figure 7C). Consistent with these results, monotherapy with VV-scFv-TIGIT or αPD-1 significantly prolonged the survival time of the tumor-bearing mice (p<0.05 or p<0.01 vs PBS). Moreover, the combination therapy further prolonged the survival time of the tumor-bearing mice (p<0.05 vs VV-scFv-TIGIT; p<0.05 vs αPD-1; p<0.001 vs PBS; figure 7D).

Next, we evaluated the antitumor efficacy of the combined application of VV-scFv-TIGIT and αLAG-3 on the CT26 model (figure 7E). Consistent with the previous results, intratumoral injection of VV-control or VV-scFv-TIGIT significantly inhibited tumor growth and prolonged the survival time of the tumor-bearing mice, whereas monotherapy with αLAG-3 did not show a stronger antitumor efficacy than PBS (figure 7F). Seven of 10 mice treated with VV-scFv-TIGIT plus αLAG-3 achieved tumor CR, whereas only 1 of 10 mice treated with αLAG-3 and 3 of 10 mice treated with VV-scFv-TIGIT achieved tumor CR (figure 7G). Consistent with these results, the combination therapy with αLAG-3 and VV-scFv-TIGIT significantly prolonged the survival time of mice compared with monotherapy with αLAG-3 or VV-scFv-TIGIT. Moreover, mice treated with VV-scFv-TIGIT plus αLAG-3 showed a longer survival time than mice treated with VV-control plus αLAG-3 (figure 7H). These results indicated that the combined treatment with αPD-1 or αLAG-3 further improved the antitumor efficacy of VV-scFv-TIGIT.

DISCUSSION

The most prominent ability of OVs is that they can turn ‘cold’ tumors into ‘hot’ tumors, thereby providing a prerequisite immune microenvironment for immune checkpoint targeted therapy. Therefore, the combination therapy using OVs and ICBs has become a new and promising cancer immunotherapy strategy. One combination approach of this strategy is the intratumoral injection of OV plus systemic administration of ICBs. Another combination approach is to modify the OV with the gene that encodes the immune checkpoint blockade so that the OV infects tumor cells and locally releases the immune checkpoint blockade. Both of these combination therapies have been shown to cause a synergistic effect of the OV and ICBs in the treatment of cancer. Previous studies have shown that the combined use of local injection of oncolytic VV and systemic administration of PD-1 blockade has higher efficacy than either monotherapy. Alternatively, engineered oncolytic VV or HSV expressing the PD-1 blockades also showed the equal antitumor effect as the combined use of OV and PD-1 blockades. In this study, we demonstrated for the first time that armed VV with a scFv against TIGIT significantly enhanced the antitumor efficacy of the parental VV by remodeling the immune status of the TME. We also demonstrated for the first time that the additional combination of PD-1 or LAG-3 blockade further enhanced the antitumor efficacy of VV armed with the scFv against TIGIT.

The previous study has shown that intratumoral injection of the control VV with TK deletion but not expressing any foreign genes resulted in the remodeling of the tumor immune microenvironment, particularly with the increasing of T cells. In the present study, we found that the control VV has only limited ability to recruit TILs in both subcutaneous and ascites tumor models. A recent study also obtained similar results in CT26, B16F10, and LLC subcutaneous tumor models, even with virus titers twice as high as ours. These findings emphasized the need to use additional immunomodulators to genetically modify VV to further improve its lymphocyte recruitment function. The most extensively used transgene is the cytomegalovirus immediate-early 1 (ICP47) or GM-CSF, which has been shown to be effective in increasing the infiltration of T-cells and macrophages. Besides, it has been shown that the vectorization of IL-15 in VV significantly enhanced its ability to recruit T cells and NK cells.

To our surprise, arming VV with scFv-TIGIT significantly improved its ability to recruit TILs in both subcutaneous and ascites tumor models. In theory, scFv-TIGIT should not have the function of directly recruiting T cells. We suspect that this may be due to scFv-TIGIT relieving the immune suppressive status of the CD8+ T cells, thereby enhancing the secretion of inflammatory cytokines and chemokines and allowing other lymphocytes to recruit into the tumor.

Compared with the subcutaneous tumor model, the ascites tumor model is a more excellent model, which can dynamically monitor the oncolytic effect of the virus and the immune response triggered by the virus by repeatedly obtaining ascites without sacrificing mice. Through dynamic observation, we found that the cell composition in the ascites of the VV-control-treated mice was still dominated by tumor cells, although it also showed a gradual increase in lymphocytes and a gradual decrease in tumor cells. However, treatment with VV-scFv-TIGIT eventually led to the disappearance of tumor cells in the ascites of mice, accompanied by a high degree of CD45+ immune-cell infiltration, indicating that the infiltration and activation of immune cells, especially CD8+ T cells, is a more
Combination therapy with αPD-1 or αLAG-3 improved the antitumor efficacy of VV-scFv-TIGIT in colon cancer models (A) Treatment scheme of CT26 subcutaneous (S.C.) tumor model with VV and αPD-1. (B) Mean tumor volume of mice. (C) Individual tumor growth curve of mice. (D) Kaplan-Meier survival curves of tumor-bearing mice. (E) Treatment scheme of CT26 S.C. tumor model with VV and αLAG-3. (F) Mean tumor volume of mice. (G) Individual tumor growth curve of mice. (H) Kaplan-Meier survival curves of tumor-bearing mice. Tumor volume was measured every 2 days. Error bars represent SD. Once the tumor volume exceeded 2000 mm$^3$, the mouse was considered dead. CR, complete remission; PR, partial remission; ns, no significant differences; *$p<0.05$; **$p<0.01$; ***$p<0.001$; ****$p<0.0001$. PBS, phosphate-buffered saline; scFv, single-chain variable fragment; TIGIT, T-cell immunoglobulin and ITIM domain; VV, vaccinia virus.
important antitumor mechanism relative to the direct oncolytic effect of the virus.\textsuperscript{43–45} Consistent with these findings, we found that treatment of mouse ascites tumor with VV-scFv-TIGIT led to a higher degree of activation of the tumor-infiltrating CD8\(^+\) T cells with expressing higher levels of CD107A, IFN-\(\gamma\), TNF-\(\alpha\), and granzyme B. Furthermore, the depletion of CD8\(^+\) T cells eliminated the therapeutic efficacy of VV-scFv-TIGIT, which was accompanied by a significant reduction of the percentage of CD3\(^+\), CD4\(^+\), NK, and NKT cells and a significant reduction of secretion of IFN-\(\gamma\), IL-6, and IL-10 in the ascites. Our study confirmed that the activation of CD8\(^+\) T cells has an indispensable role in antitumor immunity induced by VV.\textsuperscript{39}

In a previous study, the control VV significantly increased the proportion of NK cells in both B16F10 and CT26 tumors.\textsuperscript{39} However, in the present study, we did not find that the control VV and VV-scFv-TIGIT increased the proportion of NK cells in the CT26 model. We suspect that the reason for the difference may be the different doses of VV because we only used a quarter of it. Another previous study has shown that early depletion (before tumor implantation) rather than late depletion of NK cells abolished the efficacy of Newcastle disease virus plus anti-PD-1 therapy on B16-F10 tumor mice, indicating that NK cells are very important in the early stages of the OV treatment process.\textsuperscript{46} In our study, the depletion of NK cells did not significantly reduce the therapeutic efficacy of VV-scFv-TIGIT, which indicates that NK cells are not the main lymphocyte subset that mediates the antitumor immunity of VV-scFv-TIGIT. These results are consistent with our previously published results. Although oncolytic ADV increased the proportion of NK cells in the mouse liver cancer model, depletion of NK cells did not significantly affect the antitumor effect of the oncolytic ADV encoding CD137-PDL1 soluble fusion protein.\textsuperscript{43} Because TIGIT has been proven to be a checkpoint receptor for NK cells, and blocking the ‘PVR-TIGIT axis’ can prevent NK cell exhaustion and elicit potent antitumor immunity,\textsuperscript{47 48} their role should not be ignored in future clinical trials.

In this study, we found that although VV-scFv-TIGIT inhibited the growth of H22 subcutaneous tumors, it did not make the tumor regress completely. However, whether in BALB/c or C57BL/6 mice, VV-scFv-TIGIT induced a complete response to ascites tumors, which seems to indicate that asites tumors are easier to be cured than subcutaneous tumors. Similar to our research, chimeric antigen receptor-modified T (CAR-T) cells have been reported to have good efficacy on hematological tumors, but have poor efficacy on solid tumors.\textsuperscript{49} In solid tumors, CAR-T cells must overcome multiple obstacles to reach the tumor site. However, in hematological tumors, the infused CAR T can directly recognize and kill tumor cells in the blood.\textsuperscript{50} In the same way, the liquid environment of the ascites tumor might facilitate the recognition of tumor cells by immune cells. Therefore, we hypothesized that indirect treatment of primary tumors by treating the ascites they formed may be more effective. To confirm this hypothesis, we established an ascites-subcutaneous dual tumor model and then used an intraperitoneal injection of the OV for treatment. As expected, treatment of the asites resulted in a complete response of the subcutaneous tumor. Consistent with these results, we also found that mice with asites cured by OV formed immunological memory and rejected subcutaneous re-inoculation with the same tumor cells. This ‘attack-against-the-mountain’ strategy may be more suitable for certain cancers that prefer to form asites, such as ovarian, liver, and colon cancers, especially for individuals whose primary tumors are difficult to be surgically removed.

Studies have shown that activation of T cells is always accompanied by the upregulation of immune checkpoint molecules such as PD-1, TIM3, LAG3, and TIGIT, which will inhibit the excessive activation of T cells and maintain the immune homeostasis.\textsuperscript{41} In this study, we found that VV-scFv-TIGIT upregulated all these immune checkpoint molecules in ascites tumors, and the upregulation of these molecules on CD8\(^+\) T cells did not affect the therapeutic efficacy of VV. Compared with PD-1, we observed a more significant increase in LAG-3 expression on tumor-infiltrating CD8\(^+\) T cells after VV-scFv-TIGIT virotherapy in both ascites and subcutaneous tumors. In ascites tumors, although VV treatment resulted in the increase of LAG-3 on the surface of CD8\(^+\) T cells, it did not affect CD8\(^+\) T cells expressing high levels of IFN-\(\gamma\), TNF-\(\alpha\), granzyme B, and CD107A. Our findings are consistent with previous work that vaccination with VV increases the intracellular expression of LAG-3 in CD8 T cells.\textsuperscript{42} Furthermore, they highlighted that CD8\(^+\) T cells expressed high levels of LAG-3 are still functional and capable of producing effector cytokines.\textsuperscript{53} The liquid environment of ascites tumors may be conducive to these cytokines, making them less affected by the negative immune regulation of LAG-3. Unlike hematological or ascites tumors, solid tumors often have a more complex immunosuppressive TME,\textsuperscript{44} the negative immunomodulatory function of LAG-3 may play a greater role by affecting the proliferation of CD8\(^+\) T cells.\textsuperscript{42} In our study, the additional combined use of LAG-3 antibody significantly enhanced the therapeutic efficacy of VV-scFv-TIGIT on the CT26 model, suggesting that dual scFv-armed VV targeting TIGIT and LAG-3 may be a better virus engineering strategy.

In this study, we found that infection with VV upregulated the expression of PD-L1 on the surface of tumor cells. Although PD-L1 usually downregulates the activity of T cells,\textsuperscript{55 56} studies have shown that patients with higher PD-1/PD-L1 basic expression on tumors are more responsive to anti-PD-1/PD-L1 treatment.\textsuperscript{57 58} In a recent study, 70% of MC38 subcutaneous tumors completely responded to an oncolytic VV co-expressing GM-CSF and PD-L1 inhibitor (a fusion protein of PD-1 extracellular domain and the FC fragment) in combination with a PD-1 blockade.\textsuperscript{59} In another study, treatment with oncolytic VV co-expressing IL-7 and IL-12 in combination with PD-1 blockade resulted in complete remission of 100%
of CT26 subcutaneous tumors. In the present study, although the additional combination of PD-1 blockade significantly improved the therapeutic effect of VV-scFv-TIGIT on MC38 and CT26 subcutaneous tumors, the complete response rate was lower than the previous two studies. One possible reason is that the dose of VV we used in this study was lower than that used in the two previous studies (approximately one-half). More importantly, the two previous studies have armed the VV with cytokines, which can perform biological functions at very low concentrations (pg level), and in most cases, cascade amplification effects will occur. However, our recombinant VV has only inserted immune checkpoints, which may be an important defect in our study. Moreover, due to technical limitations, we did not obtain a dual scFv armed VV. In the future, further genetic engineering is needed to improve the therapeutic efficacy of our virus, such as co-expression of ICBs and cytokines related to the immune-cell activation or exploring arming the VV with two immune checkpoints.

In conclusion, our data indicated that oncolytic virotherapy using engineered VV-scFv-TIGIT was an effective strategy for cancer immunotherapy. Intratumoral injection of VV-scFv-TIGIT caused a profound reshaping of the TME from ‘cold’ to ‘hot’ status. VV-scFv-TIGIT also synergized with PD-1 or LAG-3 blockade to achieve a complete response to tumors with poor response to VV or ICB monotherapy.

Acknowledgements
The authors would like to thank Dr Xiaofei Li (Nanjing Medical University) for conducting the ELISA assay.

Contributors
SZ and JiJW designed the study. SZ, MW, TX, LX, BH, ShiquanW, and ShingW designed and performed the experiments. SZ, MW, TX, and BH analyzed the data. SZ wrote the manuscript. JD, Junhuaw, and JiJW contributed to study supervision. SZ and JiJW critically review the manuscript. All authors read and approved the final manuscript. JiJW accepts full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish.

Funding
This study was supported by the National Natural Science Foundation of China (81773255, 81472820, and 81700037), Science and Technology Innovation Foundation of Nanjing University (14913414), Natural Science Foundation of Jiangsu Province of China (BK20171098), and Nanjing University Innovation Program for the PhD Candidate, and Research Foundation for Advanced Talents of Chifeng Municipal Hospital.

Competing interests
None declared.

Patient consent for publication
Not applicable.

Ethics approval
All animal procedures and experiments were performed following the guidelines that had been approved by the Animal Care and Use Committee of the Medical School of Nanjing University.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data availability statement
Data sharing not applicable as no datasets generated and/or analyzed for this study.

Supplemental material
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

REFERENCES
1. Chiocca EA, Rabkin SD. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res 2014;2:295–300.
2. Kaufman HL, Kohlihappi FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nature Reviews Drug Discovery 2015;14:642–62.
3. Guo ZS, Lu B, Guo Z, et al. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. J Immunother Cancer 2019;15:294–47.
4. Howells A, Marelli G, Lemoine NR, et al. Oncolytic viruses-interaction of virus and tumor cells in the battle to eliminate cancer. Front Oncol 2017;7:195.
5. Marelli G, Howells A, Lemoine NR, et al. Oncolytic viral therapy and the immune system: a double-edged sword against cancer. Front Immunol 2018;9:866.
6. Park B-H, Hvarg T, Liu T-C, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008;9:533–42.
7. Chon HJ, Lee WS, Yang H, et al. Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of Immune-Checkpoint blockade. Clin Cancer Res 2019;25:1612–23.
8. Kaufman HL, Kohlihappi FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drug. Nat Rev Drug Discov 2015;14:642–62.
9. Raja J, Ludwig JM, Gettinger SN, et al. Oncolytic virus immunotherapy: future prospects for oncology. J Immunother Cancer 2018;6:140.
10. Andtbacka RHI, Kaufman HL, Collicchio F, et al. Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015;33:2780–8.
11. Zheng M, Huang J, Tong A, et al. Oncolytic viruses for cancer therapy: barriers and recent advances. Mol Ther Oncolytics 2016;4:262–6.
12. Qin S, Xu L, Yi M, et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer 2019;18:145.
13. Bommarredy PK, Shetliger M, Kaufman HL. Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol 2018;18:498–513.
14. Puzanov I, Milhem MM, Minor D, et al. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unrespectable stage IIIIB–IV melanoma. J Clin Oncol 2016;34:2619–26.
15. Ribas A, Dummer R, Puzanov I, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 2017;170:1109–19.
16. Malhotra S, Kim T, Zager J, et al. Use of an oncolytic virus secret ing GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas. Surgery 2007;141:520–9.
17. Pearl TM, Markert JM, Cassady KA, et al. Oncolytic virus-based cytokine expression to improve immune activity in brain and solid tumors. Mol Ther Oncolytics 2019;13:14–21.
18. Li J, O’Malley M, Urban J, et al. Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol Ther 2011;19:650–7.
19. Zhu Y, Hu X, Feng L, et al. Enhanced therapeutic efficacy of a novel oncolytic herpes simplex virus type 2 encoding an antibody against programmed cell death 1. Mol Ther Oncolytics 2019;15:201–13.
20. Wang G, Kang X, Chen KS, et al. An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses. Nat Commun 2020;11:1395.
21. Barthe MY, Dunlap KM, Barthe E. Tumor-localized secretion of soluble PD1 enhances oncolytic virotherapy. Cancer Res 2017;77:2952–63.
22. Vijayanakur G, McCroskery S, Palese P. Engineering Newcastle disease virus as an oncolytic vector for intratumoral delivery of immune checkpoint inhibitors and immunocytokynes. J Virol 2020;94 doi:10.1128/JVI.01775-19.
23. Kleinpeter P, Fend L, Thioudellet C, et al. Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against...
programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition. *Oncoimmunology* 2016;5:e210467.

24 Dias JD, Hemminki O, Diaconu I, et al. Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. *Gene Ther* 2012;19:988-98.

25 Jhawar SR, Thandoni A, Bommarreddy PK, et al. Oncolytic viruses-natural and genetically engineered cancer immunotherapies. *Front Immunol* 2018;9:202.

26 Harjunpää H, Guillerey C. TIGIT as an emerging immune checkpoint. *Clin Exp Immunol* 2020;200:108-19.

27 Sanchez-Correa B, Valhondo I, Hassouneh F, et al. Dnam-1 and the TIGIT/PVRIG/TACTILE axis: novel immune checkpoints for natural killer cell-based cancer immunotherapy. *Cancers* 2019;11 doi:10.3390/cancers11060877

28 Chan CJ, Andrews DM, Smyth MJ. Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer. *Curr Opin Immunol* 2012;24:246-51.

29 Chauvin J-M, Pagliano O, Fourcade J, et al. TIGIT and PD-1 impair tumor antigen-specific CD8\(^+\) T cells in melanoma. *J Clin Invest* 2015;125:2046-58.

30 Kurtulus S, Sakushi K, Ngiow S-F, et al. TIGIT predominantly regulates the immune response via regulatory T cells. *J Clin Invest* 2015;125:4053-62.

31 Rodriguez-Abreu D, Johnson ML, Hussein MA, et al. Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). *J Clin Oncol* 2020;38:9503. doi:10.1200/JCO.2020.38.15_supply.9503

32 Solomon BL, Garrido-Laguna I. TIGIT: a novel immunotherapy target moving from bench to bedside. *Cancer Immunother Immunother* 2019;7:e1758.

33 Lin C, Ren W, Luo Y, et al. Intratumoral delivery of a PD-1-blocking scFv encoded in oncolytic HSV-1 promotes antitumor immunity and synergizes with TIGIT blockade. *Cancer Res* 2020;83:632-47.

34 Guo S, Pol J, Kroemer G. Heating it up: oncolytic viruses make tumors 'hot' and suitable for checkpoint blockade immunotherapies. *Oncoimmunology* 2018;7:e1442169.

35 Chiu M, Armstrong EJL, Jennings V, et al. Combination therapy with oncolytic viruses and immune checkpoint inhibitors. *Expert Opin Biol Ther* 2020;20:635-52.

36 Martin NT, Bell JC. Oncolytic virus combination therapy: killing one bird with two stones. *Mol Ther* 2018;26:1414-22.

37 Liu Z, Ravindranathan R, Kalinski P, et al. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. *Nat Commun* 2017;8:14754.

38 Rivadeneira DB, DePeaux K, Wang Y, et al. Oncolytic viruses engineered to enforce leptin expression reprogram tumor-infiltrating T cell metabolism and promote tumor clearance. *Immunity* 2019;51:544-548-60.

39 Nakao S, Arai Y, Tassaki M, et al. Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade. *Sci Transl Med* 2020;12 doi:10.1126/scitranslmed.aax7992

40 Kowalski SJ, Liu Z, Feist M, et al. Superagonist IL-15-armed oncolytic virus elicits potent antitumor immunity and therapy that are enhanced with PD-1 blockade. *Mol Ther* 2018;26:2476-86.

41 Liu Z, Ge Y, Wang H, et al. Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2. *Nat Commun* 2018;9:4682

42 Ge Y, Wang H, Ren J, et al. Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety. *J Immunother Cancer* 2020;8.

43 Zhang Y, Zhang H, Wei M, et al. Recombinant adenovirus expressing a soluble fusion protein PO-1/CD137L subverts the suppression of CD8\(^+\) T cells in HCC. *Mol Ther* 2019;27:1906-18.

44 Bai Y, Hui P, Du X, et al. Updates to the antitumor mechanism of oncolytic virus. *Thorac Cancer* 2019;10:1031-5.

45 Lemos de Matos A, Franco LS, McFadden G. Oncolytic viruses and the immune system: the dynamic duo. *Mol Ther Methods Clin Dev* 2020;17:349-58.

46 Zamarin D, Ricca JM, Sadekova S, et al. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. *J Clin Invest* 2018;128:1413-28.

47 Zhang Q, Bi J, Zheng X, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. *Nat Immunol* 2018;19:723-32.

48 Chauvin J-M, Ka M, Pagliano O, et al. IL15 stimulation with TIGIT blockade reverses CD155-mediated NK-cell dysfunction in melanoma. *Clin Cancer Res* 2020;26:5520-33.

49 Martinez M, Moon EK. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. *Front Immunol* 2019;10:128.

50 Marofﬁ MT, Motavalli R, Saposon VA, et al. CAR T cells in solid tumors: challenges and opportunities. *Stem Cell Res Ther* 2021;12:81.

51 Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. *Immunity* 2016;44:988-1004.

52 Grosso JF, Kellerer CC, Harris TJ, et al. Lag-3 regulates CD8\(^+\) T cell accumulation and effector function in murine self- and tumor-tolerance systems. *J Clin Invest* 2007;117:3383-92.

53 Grosso JF, Goldberg MV, Getnet D, et al. Functionally distinct Lag-3 and PD-1 subsets on activated and chronically stimulated CD8\(^+\) T cells. *J Immunol* 2009:182:6659-69.

54 Zhang E, Gu J, Xu H. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors. *Mol Cancer* 2018;17:7.

55 Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. *J Exp Med* 2000;192:1027-34.

56 Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. *Nat Med* 2002;8:793-800.

57 Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. *Nature* 2014;515:568-71.

58 Topalian SL, Taube JM, Anders RA, et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. *Nat Rev Cancer* 2016;16:275-87.